NEA Management Company, LLC

In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), NEA Management Company, LLC reported 26 stock positions worth $1.6 billion. Its top holding was Trevi Therapeutics (TRVI) at 15.5% of the portfolio, followed by MBX Biosciences (MBX, 12.6%) and Monte Rosa Therapeutics (GLUE, 11.7%). Compared with Q1 2026, it opened 1 new position, sold out of 1 and reduced 2. The biggest buy was a new position in Karyopharm Therapeutics (KPTI) and the biggest sale an exit from Arcellx (ACLX).

Most Recent 13F
Q2 2026
Location
TIMONIUM, MD
CIK
0001512848
Portfolio Value
$1.6B (Q2 2026)
SEC Filing
0001072613-26-000684 ↗ filed Aug 14, 2026

Holdings Value

0$500.0M$1.0B$1.5B$2.0B Q1 2024: $1.6B Q1 2024 Q2 2024: $1.3B Q2 2024 Q3 2024: $1.8B Q3 2024 Q4 2024: $1.8B Q4 2024 Q1 2025: $1.3B Q1 2025 Q2 2025: $1.3B Q2 2025 Q3 2025: $1.8B Q3 2025 Q4 2025: $2.0B Q4 2025 Q1 2026: $1.8B Q1 2026 Q2 2026: $1.6B $1.6B Q2 2026

Holdings 26 stocks · $1.6B
TRVI Trevi Therapeutics Inc. 15.53% 13,222,228 $246.6M No change
MBX MBX Biosciences Inc. 12.56% 3,614,486 $199.5M No change
GLUE Monte Rosa Therapeutics Inc. 11.72% 7,692,298 $186.2M No change
CELC Celcuity Inc. 11.27% 1,710,561 $179.0M Reduce -25.2%
SGP Spyglass Pharma Inc. 10.36% 7,392,301 $164.6M No change
SVRA Savara Inc. 9.49% 24,471,264 $150.7M No change
ZBIO Zenas Biopharma Inc. 6.43% 4,023,219 $102.1M No change
COUR Coursera Inc. 4.57% 12,867,769 $72.6M No change
AUPH Aurinia Pharmaceuticals Inc. 4.24% 3,969,834 $67.4M No change
CRSP Crispr Therapeutics AG 3.64% 1,058,570 $57.7M No change
ORIC Oric Pharmaceuticals Inc. 2.81% 4,118,621 $44.6M No change
PHAT Phathom Pharmaceuticals Inc. 1.34% 1,960,169 $21.3M No change
KRRO Korro Bio Inc. 1.08% 1,297,893 $17.1M No change
XFOR X4 Pharmaceuticals Inc. 0.95% 3,233,743 $15.1M No change
CSBR Champions Oncology Inc. 0.66% 1,713,720 $10.6M No change
NKTX Nkarta Inc. 0.64% 3,568,781 $10.1M No change
CVRX CVRX Inc. 0.63% 1,954,440 $10.0M Reduce -3.5%
BDTX Black Diamond Therapeutics I 0.52% 4,448,757 $8.2M No change
KPTI Karyopharm Therapeutics Inc. 0.35% 576,780 $5.6M New
IVA Inventiva SA - ADR 0.35% 1,462,586 $5.5M No change
LONA Leonabio Inc. 0.27% 464,398 $4.3M No change
SNTI Senti Biosciences Inc. 0.26% 3,775,615 $4.2M No change
MRKR Marker Therapeutics Inc. 0.15% 1,625,678 $2.4M No change
OKUR Onkure Therapeutics Inc. Class A 0.14% 478,548 $2.2M No change
IMA Imagenebio Inc. 0.02% 50,005 $295K No change
GOSS Gossamer Bio Inc. 0.01% 1,000,000 $165K No change

Portfolio Sells Q1 2026 → Q2 2026
ACLX Arcellx Inc. Sold out 0.00% −19.88
CELC Celcuity Inc. Reduce -25.2% 11.27% −3.56
CVRX CVRX Inc. Reduce -3.5% 0.63% −0.46

Portfolio Buys Q1 2026 → Q2 2026
KPTI Karyopharm Therapeutics Inc. New 0.35% +0.35

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 26$1.6BTRVI, MBX, GLUE, CELC, SGP
Q1 2026 26$1.8BACLX, CELC, SGP, TRVI, SVRA
Q4 2025 27$2.0BCELC, RYTM, ACLX, TRVI, SVRA
Q3 2025 29$1.8BRYTM, ACLX, VRNA, COUR, TRVI
Q2 2025 32$1.3BACLX, VRNA, RYTM, COUR, CRSP
Q1 2025 37$1.3BACLX, VRNA, RYTM, TEM, COUR
Q4 2024 41$1.8BACLX, VRNA, TEM, RYTM, NN
Q3 2024 42$1.8BACLX, TEM, VRNA, RYTM, SVRA
Q2 2024 41$1.3BACLX, TEM, RYTM, SVRA, COUR
Q1 2024 44$1.6BACLX, CRSP, RYTM, SVRA, COUR